The completion of patient visits in NATiV3 removes timeline risk and sets up a binary catalyst in Q4 2026. Traders should position for the topline readout, which will determine the stock's trajectory — a positive result could trigger a significant re-rating given the $1.1B market cap and large addressable MASH market, while a negative result would be devastating. Monitor the H1 2026 earnings call on September 28 for cash runway updates ahead of the readout.
Price Chart
Executive Summary
Inventiva announced the last patient completed the final 72-week visit in the pivotal NATiV3 Phase 3 trial of lanifibranor for MASH, with 1,009 patients in the main cohort and 410 in the exploratory cohort. Topline results are expected in Q4 2026, with a potential regulatory submission in H1 2027 and U.S. launch in 2028 if results are favorable. This de-risks the trial timeline and brings the binary catalyst closer, but the stock remains a binary bet on the Q4 readout, with the prior 20-F showing declining revenue and widening losses.
Key Facts
- Last patient completed final 72-week visit in NATiV3 Phase 3 trial of lanifibranor for MASH.
- 1,009 patients enrolled in the main cohort (F2/F3 fibrosis) and 410 in the exploratory cohort (F1-F4).
- Topline results expected in Q4 2026; regulatory submission anticipated H1 2027 if favorable.
- Potential U.S. launch of lanifibranor in 2028, subject to FDA approval.
- Lanifibranor has FDA Breakthrough Therapy and Fast Track designations for MASH.
- H1 2026 financial results rescheduled to September 28, 2026 (from September 25).
Financial Impact
No financial figures reported in this filing. Prior 20-F (April 2026) showed 2025 revenue of $4.5M (down from $9.2M in 2024) and net loss of $354.1M.
Risk Factors
- Topline results in Q4 2026 are binary — failure would likely destroy shareholder value.
- Prior 20-F showed declining revenue ($4.5M in 2025 vs $9.2M in 2024) and widening net losses ($354.1M), indicating ongoing cash burn.
- Company is pre-revenue and will need additional capital if NATiV3 is positive but before commercialization in 2028.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005860 |
| Document: f6k_090226.htm | 0001171843-26-005860 |
| Document: 0001171843-26-005860-index-headers.html | 0001171843-26-005860 |
| Document: 0001171843-26-005860-index.html | 0001171843-26-005860 |
| Document: 0001171843-26-005860.txt | 0001171843-26-005860 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 6-K | $3.37 | awaiting T+20 | — | $3.80 (+12.93%) |
Sep 28, 2026 29d ago | 6-K | $3.53 $3.66 | ▲ +3.68% | ▲ +3.71% | $3.80 (+7.65%) |
Sep 3, 2026 7w ago | 6-K | $4.84 $3.56 | ▼ −26.45% | ▼ −25.26% | $3.80 (−21.49%) |
Jul 6, 2026 16w ago | 6-K | $3.90 $4.48 | ▲ +14.87% | ▲ +15.44% | $3.80 (−2.56%) |
Jun 12, 2026 19w ago | 6-K | $3.76 $4.30 | ▲ +14.36% | ▲ +15.11% | $3.80 (+1.06%) |
Jun 12, 2026 19w ago | 6-K | $3.85 $4.30 | ▲ +11.69% | ▲ +9.91% | $3.80 (−1.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers